{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:17:38Z","timestamp":1791861458418,"version":"4.3.4"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Aortic stenosis (AS) and obstructive coronary artery disease (CAD) often coexist, yet the impact of obstructive CAD on clinical and patient-reported outcomes in patients undergoing transcatheter aortic valve replacement (TAVR) remains a subject of ongoing debate.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To investigate the association of obstructive CAD with clinical outcomes and health status among patients with symptomatic severe AS undergoing TAVR.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This post hoc analysis of the investigator-initiated, multicenter SCOPE I (Safety and Efficacy of the Symetis ACURATE Neo\/TF Compared to the Edwards SAPIEN 3 Bioprosthesis for Transcatheter Aortic Valve Implantation by Transfemoral Approach) randomized clinical trial was conducted at 20 tertiary heart centers in Europe from February 8, 2017, to February 2, 2019, with follow-up through 3 years. Data were analyzed from February 17 through August 13, 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Presence vs absence of obstructive CAD, defined as greater than 50% stenosis in at least 1 major epicardial coronary vessel.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Parameters of interest included vital and patient-reported disease-specific health status (Kansas City Cardiomyopathy Questionnaire [KCCQ] scores, ranging from 0 to 100, with higher numbers indicating better health status), and clinical efficacy according to Valve Academic Research Consortium (VARC)-3 definitions. Analyses were conducted using the as treated population.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 732 patients with symptomatic severe AS undergoing TAVR (mean [SD] age, 82 [4] years; 416 [56.8%] female), obstructive CAD was identified in 373 (51.0%), 144 (38.6%) of whom underwent elective percutaneous coronary intervention (PCI) during the periprocedural period. At 3 years after TAVR, there were no statistically significant differences in patient-reported health status (eg, median [IQR] baseline overall KCCQ scores with CAD, 54.2 [40.3-69.8] vs without CAD, 55.2 [38.5-72.9] and at 3-year follow-up with CAD, 79.7 [64.4-90.6] vs without CAD, 82.3 [68.2-91.7]), mortality (all-cause death: 88 of 373 [24.7%] vs 76 of 359 [22.3%], adjusted hazard ratio, [HR], 0.97 [95% CI, 0.66-1.43]; cardiovascular death: 59 of 373 [17.6%] vs 51 of 359 [15.5%], adjusted HR, 0.87 [95% CI, 0.54-1.42]), and clinical efficacy of TAVR (163 of 313 [52.1%] vs 159 of 298 [53.4%]; adjusted risk ratio, 1.10 [95% CI, 0.92-1.32]) between patients with vs without obstructive CAD. Having (vs not having) obstructive CAD was associated with a numerically albeit not statistically significantly higher risk of myocardial infarction (18 of 372 [5.5%] vs 3 of 359 [1.1%]; adjusted HR, 3.83 [95% CI, 0.96-15.31]). Periprocedural PCI among patients with obstructive CAD did not improve clinical outcomes, patient-reported health status, nor the integrated end points of clinical outcomes and quality of life measures.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this post hoc analysis of SCOPE I, patients with obstructive CAD who underwent TAVR had no statistically significant differences in survival, patient-reported health status, or VARC-3 clinical efficacy compared with patients without CAD through 3 years of follow-up. Findings suggest that a tailored approach may be essential in the treatment of TAVR candidates with severe AS and CAD.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03011346<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.47111","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:00:20Z","timestamp":1765296020000},"page":"e2547111","source":"Crossref","is-referenced-by-count":5,"title":["Obstructive Coronary Artery Disease and Health Status in Transcatheter Aortic Valve Replacement"],"prefix":"10.1001","volume":"8","author":[{"given":"Daijiro","family":"Tomii","sequence":"first","affiliation":[{"name":"Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Lanz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Thiele","sequence":"additional","affiliation":[{"name":"Heart Centre Leipzig at Leipzig University, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dik","family":"Heg","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Keun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kerckhoff Heart and Thorax Centre, Bad Nauheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Joner","sequence":"additional","affiliation":[{"name":"German Heart Centre, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"M\u00f6llmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, St-Johannes-Hospital, Dortmund, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Burgdorf","sequence":"additional","affiliation":[{"name":"Heart and Vascular Centre, Bad Bevensen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Linke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology, Heart Centre Dresden, Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Redwood","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St Thomas\u2019 Hospital & Cleveland Clinic London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hilker","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, University Medical Centre, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenard","family":"Conradi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, University Heart Centre Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kerber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cardiovascular Centre Bad Neustadt, Bad Neustadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thilo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, RoMed Klinikum Rosenheim, Rosenheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Toggweiler","sequence":"additional","affiliation":[{"name":"Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Walther","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Thoracic and Thoracic Vascular Surgery, University Hospital Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Prendergast","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St Thomas\u2019 Hospital & Cleveland Clinic London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pilgrim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"25","key":"zoi251275r1","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1161\/CIRCULATIONAHA.124.070502","article-title":"Aortic stenosis and coronary artery disease: decision-making between surgical and transcatheter management.","volume":"150","author":"Tomii","year":"2024","journal-title":"Circulation"},{"issue":"25","key":"zoi251275r2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study.","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"zoi251275r3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1161\/CIRCULATIONAHA.119.043391","article-title":"Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990-2017.","volume":"141","author":"Yadgir","year":"2020","journal-title":"Circulation"},{"issue":"8","key":"zoi251275r4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.jacc.2012.10.049","article-title":"Coronary artery disease and outcomes of aortic valve replacement for severe aortic stenosis.","volume":"61","author":"Beach","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"zoi251275r5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jtcvs.2014.08.073","article-title":"The prognostic impact of concomitant coronary artery bypass grafting during aortic valve surgery: implications for revascularization in the transcatheter era.","volume":"149","author":"Thalji","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"21","key":"zoi251275r6","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/eurheartj\/ehae019","article-title":"Impact of untreated chronic obstructive coronary artery disease on outcomes after transcatheter aortic valve replacement.","volume":"45","author":"Persits","year":"2024","journal-title":"Eur Heart J"},{"issue":"6","key":"zoi251275r7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005960","article-title":"Transcatheter aortic valve implantation with or without percutaneous coronary artery revascularization strategy: a systematic review and meta-analysis.","volume":"6","author":"Kotronias","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"zoi251275r8","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.amjcard.2019.08.024","article-title":"Meta-analysis comparing outcomes in patients undergoing transcatheter aortic valve implantation with versus without percutaneous coronary intervention.","volume":"124","author":"Lateef","year":"2019","journal-title":"Am J Cardiol"},{"issue":"23","key":"zoi251275r9","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa2401513","article-title":"PCI in patients undergoing transcatheter aortic-valve implantation.","volume":"391","author":"L\u00f8nborg","year":"2024","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi251275r10","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial invasive or conservative strategy for stable coronary disease.","volume":"382","author":"Maron","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi251275r11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jacc.2023.11.002","article-title":"Outcomes according to coronary revascularization modality in the ISCHEMIA trial.","volume":"83","author":"Redfors","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"zoi251275r12","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1916370","article-title":"Health-status outcomes with invasive or conservative care in coronary disease.","volume":"382","author":"Spertus","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi251275r13","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1056\/NEJMoa2310610","article-title":"A placebo-controlled trial of percutaneous coronary intervention for stable angina.","volume":"389","author":"Rajkumar","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"zoi251275r14","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.jacc.2021.02.038","article-title":"Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research.","volume":"77","author":"G\u00e9n\u00e9reux","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"10209","key":"zoi251275r15","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/S0140-6736(19)32220-2","article-title":"Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial.","volume":"394","author":"Lanz","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"zoi251275r16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.123.012873","article-title":"Final 3-year outcomes of a randomized trial comparing a self-expanding to a balloon-expandable transcatheter aortic valve.","volume":"16","author":"Lanz","year":"2023","journal-title":"Circ Cardiovasc Interv"},{"issue":"20","key":"zoi251275r17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"9596","key":"zoi251275r18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"15","key":"zoi251275r19","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.jacc.2012.09.001","article-title":"Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document.","volume":"60","author":"Kappetein","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"zoi251275r20","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review.","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"zoi251275r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101594","article-title":"The impact of frailty on VARC-3 integrated outcomes in patients undergoing transcatheter aortic valve replacement.","volume":"4","author":"Tomii","year":"2025","journal-title":"JACC Adv"},{"issue":"18","key":"zoi251275r22","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.jcin.2021.06.041","article-title":"ACTIVATION (percutaneous coronary intervention prior to transcatheter aortic valve implantation): a randomized clinical trial.","volume":"14","author":"Patterson","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"zoi251275r23","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S0002-9149(01)01501-6","article-title":"Prevalence of coronary artery disease in patients with aortic stenosis with and without angina pectoris.","volume":"87","author":"Rapp","year":"2001","journal-title":"Am J Cardiol"},{"issue":"7","key":"zoi251275r24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jcin.2014.01.167","article-title":"Futility, benefit, and transcatheter aortic valve replacement.","volume":"7","author":"Lindman","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"issue":"23","key":"zoi251275r25","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1016\/j.jacc.2019.09.007","article-title":"Health status after transcatheter versus surgical aortic valve replacement in low-risk patients with aortic stenosis.","volume":"74","author":"Baron","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"zoi251275r26","doi-asserted-by":"publisher","first-page":"783","DOI":"10.4244\/EIJ-E-22-00038","article-title":"PCI of bystander coronary artery lesions should be performed before TAVI: pros and cons.","volume":"18","author":"Amat-Santos","year":"2022","journal-title":"EuroIntervention"},{"issue":"9","key":"zoi251275r32","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1910555","article-title":"Five-year outcomes of transcatheter or surgical aortic-valve replacement.","volume":"382","author":"Makkar","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi251275r33","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jcin.2024.02.014","article-title":"Quality of life 5 years following transfemoral TAVR or SAVR in intermediate risk patients.","volume":"17","author":"Kleiman","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"issue":"30","key":"zoi251275r34","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/eurheartj\/ehu205","article-title":"The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials.","volume":"35","author":"Anker","year":"2014","journal-title":"Eur Heart J"},{"issue":"9","key":"zoi251275r35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.124.010008","article-title":"Future of patient-reported outcomes: bringing patients\u2019 voices into health care.","volume":"17","author":"Spertus","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"45","key":"zoi251275r36","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1093\/eurheartj\/ehab246","article-title":"Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis.","volume":"42","author":"Navarese","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"zoi251275r37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCULATIONAHA.122.062714","article-title":"Survival after invasive or conservative management of stable coronary disease.","volume":"147","author":"Hochman","year":"2023","journal-title":"Circulation"},{"key":"zoi251275r27","unstructured":"A randomized, comparative effectiveness study of staged complete revascularization with percutaneous coronary intervention to treat coronary artery disease vs medical management alone in patients with symptomatic aortic valve stenosis undergoing elective transfemoral transcatheter aortic valve replacement: the COMPLETE TAVR Study. ClinicalTrials.gov identifier: NCT04634240. Last updated July 24, 2025. Accessed October 23, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04634240?term=NCT04634240&rank=1"},{"key":"zoi251275r28","unstructured":"Functional assessment in TAVI: FAITAVI. ClinicalTrials.gov identifier: NCT03360591. Last updated March 21, 2025. Accessed October 23, 2025. https:\/\/clinicaltrials.gov\/study\/NCT03360591?term=NCT03360591&rank=1"},{"key":"zoi251275r29","unstructured":"Optimal timing of transcatheter aortic valve implantation and percutaneous coronary intervention - the TAVI PCI trial. ClinicalTrials.gov identifier: NCT04310046. Last updated September 17, 2025. Accessed October 23, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04310046?term=NCT04310046&rank=1"},{"key":"zoi251275r30","unstructured":"Percutaneous coronary intervention before transcatheter aortic valve implantation: the PRO-TAVI trial. ClinicalTrials.gov identifier: NCT05078619. Last updated December 16, 2024. Accessed October 23, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05078619?term=NCT05078619&rank=1"},{"key":"zoi251275r31","unstructured":"Randomized trial of coronary artery disease assessment strategies in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. ClinicalTrials.gov identifier: NCT06559332. Last updated March 21, 2025. Accessed October 23, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06559332?term=NCT06559332&rank=1"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2842564\/tomii_2025_oi_251275_1764783096.21312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:00:21Z","timestamp":1765296021000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2842564"}},"subtitle":["A Post Hoc Analysis of the SCOPE I Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.47111","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]}}}